Revenue from operations jumped 19.6% year on year to Rs 3,262.32 crore in the quarter ended 31 March 2023.

Profit before tax in Q4 FY23 was at Rs 205.78 crore, down 17.6% as against Rs 249.82 crore recorded in Q4 FY22.

Total expenses jumped 22.96% YoY to Rs 3071.30 crore in Q4 FY23. Purchase of medicines and consumables stood at Rs 962.69 crore (up 26.88% YoY) and employee benefits expense was at Rs 987.56 crore (up 13.21% YoY).

EBITDA (excluding other income) stood at Rs 506 crore in Q4 FY23, registering a growth of 9% YoY. EBITDA margin declined to 15.5% as compared to 17% reported in the corresponding quarter previous year.

During the quarter, the company's revenue from hospitals was at Rs 1,819.77 crore (up 21.01% YoY), retail pharmacies (including opticals) stood at Rs 754.89 crore (up 30.79% YoY) and revenue from clinics came in at Rs 632.60 crore (up 7.02% YoY).

On full year basis, the company's consolidated net profit dropped 19.2% to Rs 424.91 crore despite of 16.4% rise in revenue to Rs 11,932.88 crore in FY23 over FY22.

Dr. Azad Moopen, founder chairman and managing director, Aster DM Healthcare, said, “With Covid and its associated impact behind us, we are seeing robust growth across India and GCC. FY23 has been a year of investments and capital allocation for us, witnessing an unprecedent addition of 5 hospitals, 150 Pharmacies and 7 clinics across India and GCC. We furthered our commitment for expansion in India through adding 126 Pharmacies and 91 Labs and collection centres.

Our India business continues to grow well with revenues for the quarter growing 32% YoY to Rs 804 crore and EBITDA increasing by 62% YoY to Rs 127 crore. This business is likely to continue to deliver strong growth in the coming years. Some of our hospitals have reached almost full capacity and we are adding new beds in such areas. We have made significant investments in cutting-edge medical technology, enabling the delivery of advanced treatments and procedures across various specialties.”

Alisha Moopen, deputy managing director, Aster DM Healthcare, stated, “FY23 was unprecedent for our GCC business to have 2 new hospitals, 24 Pharmacies and 6 Clinics in a year. In this year we also saw Covid Testing Revenue of FY22 actively being replaced by Core Healthcare Revenue which grew by 26% across Hospitals, Pharmacies and Clinics.

We further reinforced our commitment to research and innovation by collaborating with renowned medical institutions and industry experts. We signed MoU with John Hopkins University, University of Michigan and Netherlands. These partnerships facilitated the development and implementation of ground-breaking treatments, medical protocols, and healthcare solutions, thus advancing the frontiers of medical science and improving patient outcomes.”

Meanwhile, the firm's board has approved the appointment of Amitabh Johri and Sunil Kumar M R as joint chief financial officers and key managerial personnel of the company with effect from 25 May 2023.

Aster DM Healthcare operates in various segments of the healthcare industry, which include hospitals, clinics and retail pharmacies, and provides healthcare services to patients across economic segments in various gulf corporation council (GCC) states through its various brands, such as Aster, Medcare and Access.